

- guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. *CMAJ* 2004; 170(6):983-94.
- Smith I, Dowsett M; IMPACT Trialists. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial [abstract]. *Breast Cancer Res Treat* 2003;82 (Suppl 1):S6.
 - Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. *Ann Oncol* 2001;12:1527-32.
 - Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. *J Clin Oncol* 2003;21:4165-74.
 - Hutcheon AW, Heys SD, Sarkar TK, Ogston KN, Eremin O, Walker LG, et al. Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial [abstract 11]. *Breast Cancer Res Treat* 2003;82(Suppl 1):S6.
 - Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. *TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up* [abstract 43]. 26th San Antonio Breast Cancer Symposium; 2003 Dec 3-6; San Antonio (TX). Available: www.abstracts2view.com/bcs03/sessionindex.php?p=2 (accessed 2004 Jun 28). General session 4.1, held 2003 Dec 5 (Friday).
 - Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 1998;16:2651-8.
 - Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2003;21:3066-71.
 - Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. *J Clin Oncol* 2003;21:1195-204.
 - Henderson IC, Berry DA, Demetri GD, Cirincione CT, Goldstein LJ, Marino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. *J Clin Oncol* 2003;21:976-83.
 - Therasse P, Mauriac L, Welnicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. *J Clin Oncol* 2003;21:843-50.

Competing interests: None declared.

DOI:10.1503/cmaj.1040848

Correction

Because of an error during editing, incorrect information appeared in Table 1 of a recent article about the career choices of new medical students by Bruce Wright and associates.¹ The number of male students at the University of Alberta was 67 (58%), rather than the number reported in the table. The corrected table appears in Table 3.

Reference

- Wright B, Scott I, Woloschuk W, Brenneis F. Career choice of new medical students at three Canadian universities: family medicine versus specialty medicine. *CMAJ* 2003;170(13):1920-4.

DOI:10.1503/cmaj.1041117

Table 3: Student characteristics by university and year of entry; no. (and %) of students*

Characteristics	U of C	UBC	U of C	UBC	U of A	Total
	2001	2001	2002	2002	2002	
	n = 93†	n = 100‡	n = 95†	n = 114‡	n = 117‡	n = 519
Male	42 (45)	43 (43)	41 (43)	50 (44)	67 (58)	243 (47)
Female	51 (55)	56 (56)	54 (57)	63 (56)	49 (42)	273 (53)
Mean age, yr	24.9	24.3	24.1	24.6	23.1	24.2
Population of community where high school was completed						
< 50 000	24 (26)	23 (23)	21 (22)	33 (29)	22 (19)	123 (24)
50 000–99 999	9 (10)	15 (15)	5 (5)	23 (20)	21 (18)	73 (14)
100 000–500 000	13 (14)	16 (16)	11 (12)	18 (16)	8 (7)	66 (13)
> 500 000	46 (49)	45 (45)	57 (60)	40 (35)	66 (56)	254 (49)

Notes: U of C = University of Calgary, UBC = University of British Columbia, U of A = University of Alberta.

*Unless otherwise indicated.

†1 student did not indicate population of the community where high school was completed.

‡1 student did not indicate gender.

New letters submission process

CMAJ's enhanced eLetters feature is now the portal for all submissions to our letters column. To prepare an eLetter, visit www.cmaj.ca and click "Submit a response to this article" in the box near the top right-hand corner of any e*CMAJ* article. All eLetters will be considered for publication in the print journal.

Letters written in response to an article published in *CMAJ* are more likely to be accepted for print publication if they are submitted within 2 months of the article's publication date. Letters accepted for print publication are edited for length (usually 250 words) and house style.